GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » InnoCare Pharma Ltd (SHSE:688428) » Definitions » Book Value per Share

InnoCare Pharma (SHSE:688428) Book Value per Share : ¥3.82 (As of Dec. 2024)


View and export this data going back to 2022. Start your Free Trial

What is InnoCare Pharma Book Value per Share?

InnoCare Pharma's book value per share for the quarter that ended in Dec. 2024 was ¥3.82.

During the past 12 months, InnoCare Pharma's average Book Value Per Share Growth Rate was -8.10% per year. During the past 3 years, the average Book Value Per Share Growth Rate was -3.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.

During the past 8 years, the highest 3-Year average Book Value Per Share Growth Rate of InnoCare Pharma was 15.80% per year. The lowest was -3.80% per year. And the median was 6.00% per year.

InnoCare Pharma's current price is ¥22.45. Its book value per share for the quarter that ended in Dec. 2024 was ¥3.82. Hence, today's PB Ratio of InnoCare Pharma is 5.88.

During the past 8 years, the highest P/B Ratio of InnoCare Pharma was 3.16. The lowest was 0.94. And the median was 1.43.

Warning Sign:

InnoCare Pharma Ltd stock PB Ratio (=2.6) is close to 2-year high of 2.6.


InnoCare Pharma Book Value per Share Historical Data

The historical data trend for InnoCare Pharma's Book Value per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

InnoCare Pharma Book Value per Share Chart

InnoCare Pharma Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Book Value per Share
Get a 7-Day Free Trial 2.41 3.74 4.31 4.05 3.82

InnoCare Pharma Quarterly Data
Dec17 Dec18 Sep19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Book Value per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.05 3.99 3.92 3.86 3.82

Competitive Comparison of InnoCare Pharma's Book Value per Share

For the Biotechnology subindustry, InnoCare Pharma's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


InnoCare Pharma's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, InnoCare Pharma's PB Ratio distribution charts can be found below:

* The bar in red indicates where InnoCare Pharma's PB Ratio falls into.


;
;

InnoCare Pharma Book Value per Share Calculation

InnoCare Pharma's Book Value Per Share for the fiscal year that ended in Dec. 2024 is calculated as:

Book Value Per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(6,725-0)/1,762
=3.82

InnoCare Pharma's Book Value Per Share for the quarter that ended in Dec. 2024 is calculated as:

Book Value Per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(6,725-0)/1,762
=3.82

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Theoretically it is what the shareholders will receive if the company is liquidated. Total Stockholders Equity is a balance sheet item and equal to Total Assets less Total Liabilities of the company.

Book value may include intangible items which may come from the company's past acquisitions. Book value less intangibles is called Tangible Book.


InnoCare Pharma  (SHSE:688428) Book Value per Share Explanation

Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.

For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.


InnoCare Pharma Book Value per Share Related Terms

Thank you for viewing the detailed overview of InnoCare Pharma's Book Value per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


InnoCare Pharma Business Description

Traded in Other Exchanges
Address
No. 8 Life Science Park Road, Building 8, Zhongguancun Life Science Park, Changping District, Beijing, CHN, 102206
InnoCare Pharma Ltd is a commercial-stage biopharmaceutical company. It discovers, develops, and commercializes drugs for the treatment of cancer and autoimmune diseases. The company's main product pipeline includes orelabrutinib, ibrutinib, zanubrutinib, tafasitamab, ICP-490, ICP-B02, ICP-248, ICP-192, ICP-723, and ICP-189, among others. Its products are mainly used to treat hematological tumors, solid tumors, and autoimmune diseases. The company is also developing products for the treatment of autoimmune diseases caused by abnormal B-cell or T-cell function.
Executives
Zhao Ren Bin Director, core technical staff
Cui Ji Song Director, core technical staff
Chen Xiang Senior management, core technical personnel

InnoCare Pharma Headlines

No Headlines